Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

Future Horizons in Lung Cancer

1 - 2 Sep 2016
Royal Society of Medicine, London, United Kingdom
Immunotherapy and treatment advances in small cell lung cancer
Prof Dean Fennell - University of Leicester, Leicester, UK
Immunotherapy and treatment advances in small cell lung cancer ( Prof Dean Fennell - University of Leicester, Leicester, UK )
6 Oct 2016
Lung cancer screening in the UK
Prof John Field - University of Liverpool, Liverpool, UK
Lung cancer screening in the UK ( Prof John Field - University of Liverpool, Liverpool, UK )
6 Oct 2016
Screening, surgical cure and new developments: Future smart surgical approaches ...
Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan,...
Screening, surgical cure and new developments: Future smart surgical approaches for brain mets ( Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy )
6 Oct 2016
NSCLC biology and new therapies: Reversing resistance
Prof Michael Seckl - Imperial College London, London, UK
NSCLC biology and new therapies: Reversing resistance ( Prof Michael Seckl - Imperial College London, London, UK )
5 Oct 2016
NSCLC biology and new therapies: Immunotherapies
Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain
NSCLC biology and new therapies: Immunotherapies ( Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain )
5 Oct 2016
NSCLC biology and new therapies: Animal models of lung cancer
Prof Julian Downward - The Francis Crick Institute, London, UK
NSCLC biology and new therapies: Animal models of lung cancer ( Prof Julian Downward  - The Francis Crick Institute, London, UK )
5 Oct 2016
NSCLC biology and new therapies: Q & A
Prof Downward, Dr Rosell, Prof Seckl
NSCLC biology and new therapies: Q & A ( Prof Downward, Dr Rosell, Prof Seckl )
5 Oct 2016
Screening, surgical cure and new developments: Q & A
Dr Henschke, Prof Field, Dr Pastorino, Dr Di Meco
Screening, surgical cure and new developments: Q & A ( Dr Henschke, Prof Field, Dr Pastorino, Dr Di Meco )
5 Oct 2016
Screening, surgical cure and new developments: Current state of the art surgery
Dr Ugo Pastorino - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Screening, surgical cure and new developments: Current state of the art surgery ( Dr Ugo Pastorino - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
5 Oct 2016
Screening, surgical cure and new developments: How to organise a national screen...
Prof John Field - University of Liverpool, Liverpool, UK
Screening, surgical cure and new developments: How to organise a national screening programme ( Prof John Field - University of Liverpool, Liverpool, UK )
5 Oct 2016
Screening, surgical cure and new developments: How to avoid false positives in l...
Dr Claudia Henschke - Mount Sinai Hospital, New York, USA
Screening, surgical cure and new developments: How to avoid false positives in lung cancer screening ( Dr Claudia Henschke - Mount Sinai Hospital, New York, USA )
5 Oct 2016
Tumour heterogeneity and the impact on patient care
Dr Nicholas McGranahan - The Francis Crick Institute, London, UK
Tumour heterogeneity and the impact on patient care ( Dr Nicholas McGranahan - The Francis Crick Institute, London, UK )
5 Oct 2016
Immunotherapy in lung cancer: Q & A
Prof Giuseppe Giaccone and Dr Olivier Pardo
Immunotherapy in lung cancer: Q & A ( Prof Giuseppe Giaccone and Dr Olivier Pardo )
5 Oct 2016
Immunotherapy in SCLC
Prof Dean Fennell - University of Leicester, Leicester, UK
Immunotherapy in SCLC ( Prof Dean Fennell - University of Leicester, Leicester, UK )
5 Oct 2016
Immunotherapy in NSCLC
Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA
Immunotherapy in NSCLC ( Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA )
5 Oct 2016
Omics, early detection and novel therapies: Q & A
Dr Murrell and Dr Pardo
Omics, early detection and novel therapies: Q & A ( Dr Murrell and Dr Pardo )
5 Oct 2016
Omics, early detection and novel therapies: Metabolomics
Dr Olivier Pardo - Imperial College London, London, UK
Omics, early detection and novel therapies: Metabolomics ( Dr Olivier Pardo - Imperial College London, London, UK )
5 Oct 2016
Omics, early detection and novel therapies: Epigenetic studies
Dr Adele Murrell - University of Bath, Bath, UK
Omics, early detection and novel therapies: Epigenetic studies ( Dr Adele Murrell - University of Bath, Bath, UK )
5 Oct 2016
Small cell lung cancer: Q & A
Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicols...
Small cell lung cancer: Q & A ( Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicolson )
5 Oct 2016
Small cell lung cancer: New therapies
Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK
Small cell lung cancer: New therapies ( Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK )
5 Oct 2016
Small cell lung cancer: Current standards of care
Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK
Small cell lung cancer: Current standards of care ( Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK )
5 Oct 2016
Maintenance in NSCLC: Q & A
Dr Besse and Dr Bhosle
Maintenance in NSCLC: Q & A ( Dr Besse and Dr Bhosle )
5 Oct 2016
Maintenance in NSCLC: Arguments for
Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK
Maintenance in NSCLC: Arguments for ( Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK )
5 Oct 2016
Maintenance in NSCLC: Arguments against
Dr Benjamin Besse - Institut Gustave Roussy, Paris, France
Maintenance in NSCLC: Arguments against ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )
5 Oct 2016
We should use PDL1 and other biomarkers for selecting patients for immune checkp...
Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK
We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )
5 Oct 2016
We should not use PDL1 and other biomarkers for selecting patients for immune ch...
Prof Gordon McVie - King's College London, London, UK
We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )
5 Oct 2016
Using PDL1 and other biomarkers in patient selection for immunology: Q & A
Dr O'Brien and Prof McVie
Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )
5 Oct 2016
Current standards of care in advanced NSCLC
Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada
Current standards of care in advanced NSCLC ( Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada )
5 Oct 2016
Imaging and novel PET tracers: Q & A
Dr Giulia Veronesi and Prof Tony Ng
Imaging and novel PET tracers: Q & A ( Dr Giulia Veronesi and Prof Tony Ng )
5 Oct 2016
Imaging and novel PET tracers: The future
Prof Tony Ng - King's College London, London, UK
Imaging and novel PET tracers: The future ( Prof Tony Ng - King's College London, London, UK )
5 Oct 2016
Imaging and novel PET tracers: State of the art
Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy
Imaging and novel PET tracers: State of the art ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )
5 Oct 2016
Radiotherapy - what's new? Q & A
Dr David Landau and Prof Corinne Favire-Finn
Radiotherapy - what's new? Q & A ( Dr David Landau and Prof Corinne Favire-Finn )
5 Oct 2016
Radiotherapy in lung cancer: Future directions
Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK
Radiotherapy in lung cancer: Future directions ( Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK )
5 Oct 2016
Radiotherapy in lung cancer: Current state of the art
Prof Corinne Faivre-Finn - Christie NHS Foundation Trust, Manchester, UK
Radiotherapy in lung cancer: Current state of the art ( Prof Corinne Faivre-Finn - Christie NHS Foundation Trust, Manchester, UK )
5 Oct 2016
Metabolomics: Reversing drug resistance
Dr Olivier Pardo - Imperial College London, London, UK
Metabolomics: Reversing drug resistance ( Dr Olivier Pardo - Imperial College London, London, UK )
14 Sep 2016
Tumour heterogeneity and the impact on patient care
Dr Nicholas McGranahan - The Francis Crick Institute, London, UK
Tumour heterogeneity and the impact on patient care ( Dr Nicholas McGranahan - The Francis Crick Institute, London, UK )
14 Sep 2016
Developing new models in SCLC
Prof Caroline Dive - Cancer Research UK Manchester Institute, Manchester, UK
Developing new models in SCLC ( Prof Caroline Dive - Cancer Research UK Manchester Institute, Manchester, UK )
14 Sep 2016
Future of imaging in lung cancer
Prof Tony Ng - King's College London, London, UK
Future of imaging in lung cancer ( Prof Tony Ng - King's College London, London, UK )
14 Sep 2016
Understanding the mechanisms of immunotherapy in lung cancer
Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain
Understanding the mechanisms of immunotherapy in lung cancer ( Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain )
14 Sep 2016
PDL1 and other biomarkers for selecting patients for immune checkpoint therapies
Dr Mary O'Brien - The Royal Marsden NHS Foundation Trust, London, UK
PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O'Brien - The Royal Marsden NHS Foundation Trust, London, UK )
14 Sep 2016
State of the art imaging and lung cancer management
Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy
State of the art imaging and lung cancer management ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )
14 Sep 2016
Future smart surgical approaches for brain metastases
Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan,...
Future smart surgical approaches for brain metastases ( Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy )
14 Sep 2016
Future directions in radiation medicine
Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK
Future directions in radiation medicine ( Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK )
14 Sep 2016
How to avoid false positives in lung cancer
Dr Claudia Henschke - Mount Sinai Hospital, New York, USA
How to avoid false positives in lung cancer ( Dr Claudia Henschke - Mount Sinai Hospital, New York, USA )
14 Sep 2016
Current state of the art radiotherapy in lung cancer
Prof Corinne Faivre-Finn - The Christie NHS Foundation Trust, Manchester, UK
Current state of the art radiotherapy in lung cancer ( Prof Corinne Faivre-Finn - The Christie NHS Foundation Trust, Manchester, UK )
14 Sep 2016
Maintenance in NSCLC
Dr Benjamin Besse - Institut Gustave Roussy, Paris, France
Maintenance in NSCLC ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )
14 Sep 2016
Recent advances and emerging therapies in lung cancer
Prof McVie, Prof Dive, Dr Nicolson and Prof Seckl
Recent advances and emerging therapies in lung cancer ( Prof McVie, Prof Dive, Dr Nicolson and Prof Seckl )
5 Sep 2016